Cervical cancer

Each year, more than half a million women are diagnosed with cervical cancer and the disease results in over 300 000 deaths worldwide. High-risk subtypes of the human papilloma virus (HPV) are the cause of the disease in most cases. The disease is largely preventable. Approximately 90% of cervical c...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The Lancet (British edition) Ročník 393; číslo 10167; s. 169 - 182
Hlavní autori:	Cohen, Paul A, Jhingran, Anjua, Oaknin, Ana, Denny, Lynette
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Elsevier Ltd 12.01.2019 Elsevier Limited
Predmet:	Bevacizumab Cancer Cervical cancer Cervix Chemoradiotherapy Female Fertility Global Health Health risk assessment Healthcare Disparities - statistics & numerical data HIV Human immunodeficiency virus Human papillomavirus Humans Hysterectomy Immunotherapy Incidence Income Mass Screening - methods Mass Screening - statistics & numerical data Metastases Monoclonal antibodies Mortality Neoplasm Staging Papillomavirus Infections - epidemiology Papillomavirus Vaccines - immunology Poverty Radiation therapy Risk Factors Screening Solid tumors Targeted cancer therapy Toxicity Uterine Cervical Neoplasms - diagnosis Uterine Cervical Neoplasms - epidemiology Uterine Cervical Neoplasms - prevention & control Uterine Cervical Neoplasms - therapy Vaccination Vaccines Vascular endothelial growth factor Viruses Womens health United States > US South Africa Africa
ISSN:	0140-6736, 1474-547X, 1474-547X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	Each year, more than half a million women are diagnosed with cervical cancer and the disease results in over 300 000 deaths worldwide. High-risk subtypes of the human papilloma virus (HPV) are the cause of the disease in most cases. The disease is largely preventable. Approximately 90% of cervical cancers occur in low-income and middle-income countries that lack organised screening and HPV vaccination programmes. In high-income countries, cervical cancer incidence and mortality have more than halved over the past 30 years since the introduction of formal screening programmes. Treatment depends on disease extent at diagnosis and locally available resources, and might involve radical hysterectomy or chemoradiation, or a combination of both. Conservative, fertility-preserving surgical procedures have become standard of care for women with low-risk, early-stage disease. Advances in radiotherapy technology, such as intensity-modulated radiotherapy, have resulted in less treatment-related toxicity for women with locally-advanced disease. For women with metastatic or recurrent disease, the overall prognosis remains poor; nevertheless, the incorporation of the anti-VEGF agent bevacizumab has been able to extend overall survival beyond 12 months. Preliminary results of novel immunotherapeutic approaches, similarly to other solid tumours, have shown promising results so far.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23
ISSN:	0140-6736 1474-547X 1474-547X
DOI:	10.1016/S0140-6736(18)32470-X